The densities of PD-1+ immune cells and PD-L1+ tumor cells were highest in tumors from patients CRC03 and CRC13 (Figure 6C), suggesting that these patients are candidates for immunotherapy with anti-PD-1/anti-PD-L1 antibodies. The gene discussed is CD274; the disease is neoplasm.